AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02648373 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Patients receive no additional intervention. They will begin physical therapy and receive care at the therapist's discretion.
Study NCT04053881 — intervention group
Intervention type: DRUG
Intervention: Certolizumab pegol
Description: Active Substance: Certolizumab Pegol Pharmaceutical Form: Prefilled syringe Concentration: 200 mg/ml Route of Administration: Subcutaneous injection
Study NCT00006170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: smoking cessation medication aid
Study NCT00006170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: smoking cessation medication aid
Study NCT00006170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: A matched placebo pill
Study NCT04462653 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable Dynamic ECG Recorder
Description: use a Wearable Dynamic ECG Recorder to record heart rate and atrial fibrillation
Study NCT04462653 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 12-lead ECG recordings
Description: use a 12-lead ECG recordings to record heart rate and atrial fibrillation
Study NCT02827851 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liposuction
Study NCT02827851 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SVF isolation
Description: SVF will be isolated according to patent pending technology based on enzymatic digestion, washing and concentration of cell pellet in 5 ml of Hartmann's solution.
Study NCT00006170 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A matched placebo pill
Study NCT00006170 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: weight concerns intervention
Description: cognitive behavioral treatment to address weight concners
Study NCT00793468 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nicotine Replacement Transdermal Patch
Description: All subjects will be treated during the 4 week open-label smoking cessation phase of the study. During Weeks 1-3, subjects will receive 21mg/day, and during Week 4, subjects will receive 14 mg/day. Those subjects who reached continuous abstinence on at least week 4 of the open-label phase will receive 7mg/day during Week 5 while taking GSK598809 or placebo.
Study NCT00793468 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily for 12 weeks
Study NCT00006170 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: weight concerns intervention
Description: cognitive behavioral treatment to address weight concners
Study NCT01373502 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DES Limus Carbostent
Description: DES Limus Carbostent Carbofilm Coated Coronary Stent
Study NCT01373502 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Taxus Liberté Stent
Description: Taxus Liberté Coronary Stent
Study NCT00006170 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: smoking cessation intervention
Description: Cognitive behavioral intervention for smoking cessation
Study NCT00006170 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: smoking cessation intervention
Description: Cognitive behavioral intervention for smoking cessation
Study NCT01517724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1.3mg/sq m, subcutaneous injection, days 1, 8, 15 and 22 of 28 day cycle; maximum of 8 cycles
Study NCT01816971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given IV or PO
Study NCT01816971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carfilzomib
Description: Given IV
Study NCT01816971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given PO
Study NCT01816971 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Description: Undergo autologous hematopoietic stem cell transplant
Study NCT01816971 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03818490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bergamot Aromatherapy
Description: Patients in this group inhaled bergamot essential oil for 15 minutes.
Study NCT03708328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomvastomig
Description: Lomvastomig will be administered intravenously (IV) with a flat dose on the schedule described for each study arm.
Study NCT05020223 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vital pulp therapy
Description: Vital pulp therapy different modalities for management of deep carious lesion in primary teeth
Study NCT01247129 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delay procedure of SIEA flap.
Description: Ligating the deep inferior epigastric artery ipsilaterally to the planned raising of the SIEA flap 2 weeks prior to the reconstructive procedure.
Study NCT04545008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Oral Famotidine
Study NCT04545008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetyl cysteine
Description: Oral N-Acetyl Cysteine
Study NCT00454558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas, BAY63-2521)
Description: Biweekly uptitration of BAY63-2521 (Oral sGC Stimulator) starting from 1.0 mg TID up to 2.5 mg TID in steps of +0.5 mg according to safety and tolerability.
Study NCT03557619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: tablet; oral
Study NCT03557619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ethinyl estradiol/levonorgestrel
Description: tablet; oral
Study NCT01311271 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: 1 Hz frequency, 15 minutes, intensity of 90% resting motor threshold, with one session a day,~* Real: unaffected M1 hotspot~* Sham: coil perpendicular to scalp
Study NCT01311271 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: 1 Hz frequency, 15 minutes, intensity of 90% resting motor threshold, with one session a day,~* Real: unaffected M1 hotspot~* Sham: coil perpendicular to scalp
Study NCT01004497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: After the completion of each induction and consolidation chemotherapy with recovery of leukocyte and platelet counts, dasatinib will be given as an alternative manner: 100 mg by mouth once daily for 4 weeks
Study NCT01004497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300 mg/m2, IV for 2 hours, every 12 hours x 6 doses, days 1-3
Study NCT01004497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4 mg/m2/day (maximum 2 mg/day), IV for 30 minutes, days 4 \& 11
Study NCT01004497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: 45 mg/m2/day, IV for 1 hour, days 4 \& 11
Study NCT01004497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg/day, IV push, days 1-4 \& days 11-14
Study NCT01004497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 2 g/m2, IV for 3 hours, every 12 hours x 10 doses, days 1-5
Study NCT01004497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: 12 mg/m2/day, IV for 30 minutes, days 1-2
Study NCT04748562 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: Taking prontogest vaginally
Study NCT04304430 — intervention group
Intervention type: DRUG
Intervention: Dapagliflozin
Description: Initiation of dapagliflozin according to clinical indication
Study NCT04304430 — intervention group
Intervention type: DRUG
Intervention: DPP-4 inhibitor
Description: Initiation of DPP-4i according to clinical indication
Study NCT01453595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEZ235
Description: BEZ235 will be taken orally twice daily starting on Day 1, Cycle 1, self-administration will continue twice daily on a continuous schedule with cycle length defined as 28 days. Increasing dosing levels of BEZ235 will be studied sequentially (beginning with Dose Level 1, BEZ235 400mg by mouth twice daily) as per the treatment noted below.~Cohort-1a BEZ235 300 mg by mouth twice daily Cohort 1 BEZ235 400 mg by mouth twice daily Cohort 2 BEZ235 600 mg by mouth twice daily Cohort 3 BEZ235 800 mg by mouth twice daily
Study NCT02098200 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TriCinch System
Description: Percutaneous treatment of Tricuspid Regurgitation
Study NCT02047838 — intervention group
Intervention type: OTHER
Intervention: Anti-mullerian hormone (AMH) level dosage.
Study NCT02047838 — intervention group
Intervention type: OTHER
Intervention: Follicle-stimulating hormone (FSH) level dosage.
Study NCT02047838 — intervention group
Intervention type: OTHER
Intervention: Antral follicle count (AFC).
Study NCT01097967 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Study NCT02786082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20mg Azilsartan Tablets
Description: Strength: 20mg, oral administration 1 tablet/ day
Study NCT02786082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40mg Azilsartan Tablets
Description: Strength: 40mg, oral administration 1 tablet/ day
Study NCT02732366 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based exercise and peer coaching
Description: Group-based exercise and peer coaching will take place over 6 weeks plus one booster visit after 3 months, and include physical therapist-led 1 hour sessions 2 times per week for 2 weeks followed by once per week for 4 weeks (8 sessions) to include: progressive strengthening, balance and mobility exercises; patient goal setting; peer coaching training activities to teach group members ways to help each other to meet their exercise goals during and after classes are over. There will be an individualized home program including flexibility, strengthening, walking, and balance, as well as activity monitoring.
Study NCT02732366 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual PT and attention control grp class
Description: The usual PT and attention control group class will receive standard one-on-one PT strength, balance, gait and education intervention, and group classes to provide valuable information about healthy living, including nutrition, relaxation, and stress management. The attention control - healthy living group classes will take place over 6 weeks plus one booster visit after 3 months, and include 1 hour sessions 2 times per week for 2 weeks followed by once per week for 4 weeks (8 sessions).
Study NCT04682496 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intratendon vascularization
Description: Ultrasonic exploration by power-Doppler of the intratratendon vascularization, making longitudinal cuts of the patellar tendon and with previously pre-established Doppler optimization parameters for all patients. The optimization parameters of the power-Doppler signal will be set at a Doppler frequency of 6.7 MHz, pulse repetition frequency (PRF) of 0.7 kHz. The lowest wall filter and a standardized gain just below the level that produces random noise will be applied. This examination will be repeated several times with different probe pressures, which will be quantitatively adjusted through the force sensor and maintained with the articulated arm. A 4-second static video will be recorded of the longitudinal section that presents a higher Doppler signal in each of the scans at different probe pressures.
Study NCT02191982 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walk With Ease
Description: Walk With Ease is the Arthritis Foundation's evidence-based walking intervention to help with fatigue and pain. The intervention is a self-directed program that helps guide participants in a safe and comfortable paced walking program with an ultimate goal of walking for 30 minutes a day, five days a week.
Study NCT02191982 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walk With Ease
Description: Walk With Ease is the Arthritis Foundation's evidence-based walking intervention to help with fatigue and pain. The intervention is a self-directed program that helps guide participants in a safe and comfortable paced walking program with an ultimate goal of walking for 30 minutes a day, five days a week.
Study NCT00788996 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief intervention based in clinical practice guide
Description: Minimal counseling at smoking parents with babies minor 1 year-old
Study NCT04484467 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Food Supplement With Standardized Menthol, Limonene, and Ginger
Description: Components of Standart Zdorovya GASTRO: Peppermint oil (40% menthol, 1.5% limonene) - 240 mg, Ginger oil (14% gingerol) - 50 mg, olive oil - 440 mg, 1 capsule, 730 mg, once a day for 30 days
Study NCT04484467 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Components of placebo Olive oil - 730 mg, 1 capsule, 730 mg, once a day for 30 days
Study NCT02235948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: folic acid supplementation
Description: 0.8mg folic acid/day
Study NCT04189562 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS Intervention
Description: Delivery of text messages will use the text messaging program Simple Online Family Intervention for ADHD (SOFIA).
Study NCT02959996 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine
Description: liposomal bupivacaine injection in the Pfannenstiel incision
Study NCT02959996 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo injection in the Pfannenstiel incision
Study NCT00722761 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: drospirenone and ethinyl estradiol
Description: Drosperinone (3mg) and ethinyl estradiol (0.02mg) tablet given once daily for 24 weeks
Study NCT00722761 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Placebo tablet (no active drug) given once daily for 24 weeks
Study NCT02393794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Histone deacetylase inhibitor
Study NCT01061112 — intervention group
Intervention type: DRUG
Intervention: Flurbiprofen Control - Flurbiprofen Only
Description: A single 50 mg flurbiprofen dose taken at the start of the study period. No other drugs administered during this study period.
Study NCT01061112 — intervention group
Intervention type: DRUG
Intervention: Flurbiprofen Inhibition - Flurbiprofen & Fluconazole
Description: A single 50 mg flurbiprofen dose taken at the start of the study period. 400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
Study NCT01061112 — intervention group
Intervention type: DRUG
Intervention: Ketoprofen Control - Ketoprofen Only
Description: A single 75 mg ketoprofen dose taken at the start of the study period. No other drugs administered during this study period.
Study NCT01061112 — intervention group
Intervention type: DRUG
Intervention: Ketoprofen Inhibition - Ketoprofen & Fluconazole
Description: A single 75 mg ketoprofen dose taken at the start of the study period. 400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
Study NCT01061112 — intervention group
Intervention type: DRUG
Intervention: Tolbutamide Control - Tolbutamide Only
Description: A single 500 mg tolbutamide dose taken at the start of the study period. No other drugs administered during this study period.
Study NCT01061112 — intervention group
Intervention type: DRUG
Intervention: Tolbutamide Inhibition - Tolbutamide & Fluconazole
Description: A single 500 mg tolbutamide dose taken at the start of the study period. 400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
Study NCT01702220 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: 6-12 sessions of CBT in person or over the phone
Study NCT01702220 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ECC
Description: 6 biweekly sessions of ECC over the telephone
Study NCT02503124 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single night's wake therapy
Description: Eligible patients are assisted in maintaining total sleep deprivation during one night
Study NCT02503124 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bright light
Description: Bright light according to patients´ own circadian rhythm each morning for a week.
Study NCT02503124 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual - inpatient care
Description: All patients are admitted due to severe depression and are under observation and most receive antidepressive medication and if necessary anxiolytic/antipsychotic medication.
Study NCT02503124 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual - inpatient care
Description: All patients are admitted due to severe depression and are under observation and most receive antidepressive medication and if necessary anxiolytic/antipsychotic medication.
Study NCT02503124 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informative meeting
Description: A short sleep hygiene consultation.
Study NCT02503124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment as usual - medicine
Description: Since all patients are admitted due to a severe mental illness, they will receive medication according to indication. Most patients have already tried more than one antidepressant at the time of admission. In cases of severe anxiety, anxiolytics are prescribed but this is kept to a minimum.
Study NCT02503124 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual - medicine
Description: Since all patients are admitted due to a severe mental illness, they will receive medication according to indication. Most patients have already tried more than one antidepressant at the time of admission. In cases of severe anxiety, anxiolytics are prescribed but this is kept to a minimum.
Study NCT02368223 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: YouGrabber
Description: 2 weeks of home-based therapy with a virtual-reality enhanced upper limb training system
Study NCT02149979 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Temperature Controlled Laser Soldering
Description: This study had a prospective within-subject design. Patients allocated to laparoscopic cholecystectomy procedure were enrolled. After the completion of the laparoscopic cholecystectomy surgical procedure, 4 trocar port sites were randomly either sutured or laser soldered by employing the temperature-controlled laser soldering system.
Study NCT01976429 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: flight/diving simulation
Description: measurement of ET function during simulated flight/diving in pressure chamber
Study NCT01976429 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ET function testing at ambient pressure
Description: ET function testing at ambient pressure using sonometry, tubomonometry, 9-step test, maneuver sequence
Study NCT01976429 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: nasal video-endoscopy
Description: examination of nose, nasopharynx,and Eustachian tube orifice
Study NCT05311059 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic ovarian drilling
Description: Drilling needle was introduced and connected by monopolar current, held against ovarian surface for 4 seconds using a power of 40 watt, 4 puncture was done in each ovary with putting into consideration that the puncture must be not superficial and it must go deep through the main substance of the ovary
Study NCT02514720 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: cigarette
Description: Participants will be allowed to smoke a cigarette prior to a PET scan and be abstinent from smoking prior to the other PET scan
Study NCT03355274 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transcutaneous Oximetry
Description: The examination of transcutaneous Oximetry dynamic measurement with palmar face of both forearms during two consecutive maneuvers known as the candlestick (hands up).
Study NCT03355274 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous Oximetry
Description: The examination of transcutaneous Oximetry dynamic measurement with palmar face of both forearms during two consecutive maneuvers known as the candlestick (hands up).
Study NCT03355274 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Photopletysmography
Description: Maneuvers are repeted with the photoplestysmography sensors and in front of a Kinect camera.
Study NCT03355274 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Photopletysmography
Description: Maneuvers are repeted with the photoplestysmography sensors and in front of a Kinect camera.
Study NCT03355274 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires of Quality of Life (QoL)
Description: Each subject complete 2 QoL questionnaires : Sf-12 (Short Form 12) and DASH (Disabilities of the Arm, Shoulder and Hand).